



Immune Design
Investor Relations Department
Immune Design Corp. Attn:
Accounts Payab
601 Gateway Blvd. Suite 250
South San Francisco, CA 94080
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: IMDZ

Last Trade:	6.55
Trade Time:	4:00 PM ET Oct 18, 2017
Change:	-1.65 ↓ (- 20.122%)
Day Range	6.38 - 8.35
52-Week Range	4.50 - 13.05
Volume	2,200,199

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [Oct 16, 2017
Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients](#)
- [Sep 25, 2017
Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting](#)
- [Sep 8, 2017
New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response](#)
- [Sep 1, 2017
Immune Design to Present at Upcoming Investor Conferences in September](#)
- [Aug 30, 2017
Immune Design Announces New CMB305 + Checkpoint Inhibitor Topline Data from an Upcoming Presentation at the ESMO 2017 Congress](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- [Mar 7, 2017
Annual Report \(10-K\)](#)
- [Apr 26, 2017
Proxy Statement \(DEF 14A\)](#)
- [Aug 2, 2017
Quarterly Report \(10-Q\)](#)
- [May 4, 2017
Quarterly Report \(10-Q\)](#)
- [Nov 9, 2016
Quarterly Report \(10-Q\)](#)